• Accueil >
  • Publications >
  • Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma

Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma

23 sept. 2021New England Journal of Medicine

DOI : 10.1056/nejmoa2103485

Auteurs

Paul Nathan, Jessica C. Hassel, Piotr Rutkowski, Jean-Francois Baurain, Marcus O. Butler, Max Schlaak, Ryan J. Sullivan, Sebastian Ochsenreither, Reinhard Dummer, John M. Kirkwood, Anthony M. Joshua, Joseph J. Sacco, Alexander N. Shoushtari, Marlana Orloff, Josep M. Piulats, Mohammed Milhem, April K.S. Salama, Brendan Curti, Lev Demidov, Lauris Gastaud, Cornelia Mauch, Melinda Yushak, Richard D. Carvajal, Omid Hamid, Shaad E. Abdullah, Chris Holland, Howard Goodall, Sophie Piperno-Neumann